1.41

11.32% -0.18

After Hours: 1.42 0.01 +0.71%

Annovis Bio Inc (ANVS)

Overview News Price History Why ANVS Down? Discussions Forecast

Annovis Bio Inc stock is traded at $1.41, with a volume of 275.08K. It is down -11.32% in the last 24 hours and down -14.55% over the past month. Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.

Previous Close:

$1.59

Open:

$1.54

24h Volume:

275.08K

Relative Volume:

0.58

Market Cap:

$27.48M

Revenue:

Net Income/Loss:

$-40.94M

P/E Ratio:

-0.3672

EPS:

-3.84

Net Cash Flow:

$-22.97M

1W Performance:

-23.78%

1M Performance:

-14.55%

6M Performance:

-82.42%

1Y Performance:

-87.51%

1-Day Range:

$1.40

$1.54

1-Week Range:

$1.40

$1.74

52-Week Range:

$1.40

$20.00

Annovis Bio Inc Stock (ANVS) Company Profile

Name

Annovis Bio Inc

Sector

Healthcare (1182)

Industry

Biotechnology (678)

Phone

484-875-3192

Address

101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA

Employee

Twitter

Next Earnings Date

2024-12-11

Latest SEC Filings

ANVS's Discussions on Twitter

Compare ANVS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANVS Annovis Bio Inc	1.41	27.48M	0	-40.94M	-22.97M	-3.84
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	68.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-10-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-25-24	Upgrade	Maxim Group	Hold → Buy
Dec-29-23	Initiated	Canaccord Genuity	Buy
Jul-07-21	Reiterated	Maxim Group	Buy

Annovis Bio Inc Stock (ANVS) Latest News

Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025

Mar 30, 2025

Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN

Mar 30, 2025

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa

Mar 27, 2025

Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener

Mar 27, 2025

Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com

Mar 27, 2025

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire

Mar 27, 2025

NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan

Mar 27, 2025

Mar 26, 2025

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire

Mar 26, 2025

Mar 25, 2025

Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews

Mar 25, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN

Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025

Annovis Bio Inc. to Present Key Findings at AD/PD™ 2025 Conference in Vienna on Alzheimer's and Parkinson's Treatments - Nasdaq

Mar 25, 2025

Game-Changing Phase 3 Results: Annovis Reveals Dual Breakthrough in Parkinson's and Alzheimer's Treatment - Stock Titan

Mar 25, 2025

Mar 21, 2025